This study demonstrates that suppressed NOXA expression leads to an MCL-1-mediated resistance to venetoclax in SS, thus revealing an Achilles’ heel that can be exploited by concomitant treatment with an MCL-1 inhibitor. Here, MCL1 is linked to synovial sarcoma.